Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II (ACNASE)
Primary Purpose
Acne Vulgaris
Status
Unknown status
Phase
Phase 3
Locations
Brazil
Study Type
Interventional
Intervention
Benzoyl Peroxide 5% and Sulphur 2%
Vehicle of Acnase
Sponsored by
About this trial
This is an interventional treatment trial for Acne Vulgaris focused on measuring Acnase, Acne Vulgaris, Safety, Efficacy
Eligibility Criteria
Inclusion Criteria:
- Age: 12 to 35 years;
- Oily skin with tendency to acne;
- Presence of non-inflammatory lesions and inflammatory, acne vulgaris diagnosed as grade I or II, as the following: I) Comedones - only comedones; II) Papulopustular - comedones, papules and pustules; III) Nodulocystic - comedones, papules, pustules, nodules and cysts; IV) Conglobates - severe acne, usually affects other areas of the body, out of preference, giving comedones, papules, pustules, abscesses, confluent nodules, cysts and scars.
- Agreement in compliance with the procedures of the trial and attend the clinic on certain days and times for medical evaluations and scores of injuries acne;
- Signing of the Term of Free and Informed Consent and agreement of the lowest in the case of patients between 12 and 17 years.
Exclusion Criteria:
- Pregnancy (pregnancy test by urinary indication to women voluntary of childbearing age);
- Nursing;
- Nodulocystic and Conglobates acne;
- Conditions associated hormone (tireoid disease, micropolicysts ovaries, adrenal or pituitary disorders);
- Drug use systemic corticosteroids, anticonvulsants, photo-sensibility and / or new drugs for up to 01 months before the selection;
- Use of topical therapy, systemic or physical (cleaning of the skin) for the treatment of acne at least 01 months before the selection;
- History of atopic or allergic skin;
- History of hypersensitivity to Benzoyl peroxide or sulfur;
- Skin Conditions active (and / or spread) that may interfere with the outcome of the study;
- Beginning or end-use of contraceptives; (for females)
- Sunlight intense exposure until 01 months before the assessment;
- Aesthetic treatments, skin up to 01 months before the selection;
- Use of specific oily cosmetic for skin / acne and makeup, facial moisturizing, etc..;
- Use of the drug Acnase prior to inclusion in the study.
Sites / Locations
- Medcin Instituto da Pele Ltda.
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Acnase
Vehicle
Arm Description
Outcomes
Primary Outcome Measures
Average clinical development of target lesions of the groups for each experimental time.
Secondary Outcome Measures
Clinical evolution of the acne through the counting of inflammatory and non - inflammatory lesions.
Evaluation of oily skin through the clinical evaluation with four-point scale (absent, mild, moderate, intense)
Observation of occurrence and intensity of clinical parameters erythema, scaling, itching and burning through the clinical evaluation with four-point scale (absent, mild, moderate, severe).
Full Information
NCT ID
NCT00877409
First Posted
April 6, 2009
Last Updated
April 6, 2009
Sponsor
Zurita Laboratorio Farmaceutico Ltda.
1. Study Identification
Unique Protocol Identification Number
NCT00877409
Brief Title
Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II
Acronym
ACNASE
Official Title
A Monocentric, Single-Blind, Randomized, Placebo-Controlled Study of the Safety and Efficacy of the Topical Drug Acnase Creme in the Treatment of Acne Vulgaris I and II
Study Type
Interventional
2. Study Status
Record Verification Date
April 2009
Overall Recruitment Status
Unknown status
Study Start Date
April 2009 (undefined)
Primary Completion Date
July 2009 (Anticipated)
Study Completion Date
July 2009 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Zurita Laboratorio Farmaceutico Ltda.
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The objective of this study is to establish the safety in use of the topical drug Acnase Creme and its effectiveness in treatment of acne grade I (comedones) and II (comedones, papules, pustules).
Detailed Description
The acne is a common dermatosis in dermatological practice, affects more than 80% of the population during the second and third decades of life. It is found worldwide, with no evidence of racial or ethnic differences that influence the susceptibility to its development. However there is influence of genetic factors, hormones, the use of certain drugs that may have previous or aggravate the disease.
It is an inflammatory disease of the follicle polissebáceo, which consists of large sebaceous glands, multiacinares, rudimentary hair follicle and a channel comprising a acro-infundibulum in its upper portion and an infra-infundibulum in the dermal portion.
This is a benign condition, self-limited, but can cause serious psychological problems or disfiguring scars, which can persist for the rest of life.
The initial change is a disorder of follicular epithelial differentiation, during which the cornea cells (keratinocytes) which are the follicle polissebáceo are excessively released in the lumen. The result of this event is the appearance of the precursor, microcomedão, from which the lesions of acne are developed (closed comedones, open comedones, papules, pustules and nodules). The dilation of the follicular infundibulum with the material produces a corneal comedão closed. This is the first clinically visible lesions of acne. As hyperkeratosis extends to the upper infundibulum, extended its opening, it formed the comedão open.
The pathogenesis of acne is complex and understood only in part. The follicular occlusion with adherent keratinocytes and activation of hormone secretion resulting in the formation of sebaceous microcomedão. Studies suggest that free fatty acids intrafoliculares control inflammation through chemotactic properties on leukocytes, monocytes and neutrophils. The free fatty acids may provide the primary stimulus for the retention hyperkeratosis follicularis. Moreover, tallow provides a favorable substrate for the proliferation of Propiniobacterium acnes (P. acnes). Studies suggest that P. acnes, a microaerophilic bacterium (almost anaerobic), Gram-positive, has a lipase able to hydrolyze triglycerides in sebum into free fatty acids. Therefore, these pathogens play critical role in the generation of inflammatory lesions. The P. acnes produces proteases and neuroaminidases, which may increase the permeability of the follicular epithelium. Also produce a chemotactic factor of low molecular weight that selects the polymorphonuclear leukocytes. In the process of phagocytosis of bacteria are released hydrolases, which break the integrity of the follicular wall. Subsequently, the content intrafolicular - fragments of keratin, fat, hair, and P. acnes - is expelled to the dermis.
If surface aggregation of neutrophils, as was a wheal, and with the presence of purulent secretion, a pustule. With the infiltration of inflammation deep and extensive, a nodule or cyst is produced.
Clinically, the eruption acnéica is located predominantly in the face (90%) and to a lesser extent, in the back (60%) and chest (15%). As young man, mainly affects the face, while in older, the back.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acne Vulgaris
Keywords
Acnase, Acne Vulgaris, Safety, Efficacy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Acnase
Arm Type
Active Comparator
Arm Title
Vehicle
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Benzoyl Peroxide 5% and Sulphur 2%
Other Intervention Name(s)
Acnase
Intervention Description
The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Intervention Type
Drug
Intervention Name(s)
Vehicle of Acnase
Other Intervention Name(s)
Control, Vehicle, Placebo
Intervention Description
The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
Primary Outcome Measure Information:
Title
Average clinical development of target lesions of the groups for each experimental time.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Clinical evolution of the acne through the counting of inflammatory and non - inflammatory lesions.
Time Frame
12 weeks
Title
Evaluation of oily skin through the clinical evaluation with four-point scale (absent, mild, moderate, intense)
Time Frame
12 weeks
Title
Observation of occurrence and intensity of clinical parameters erythema, scaling, itching and burning through the clinical evaluation with four-point scale (absent, mild, moderate, severe).
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age: 12 to 35 years;
Oily skin with tendency to acne;
Presence of non-inflammatory lesions and inflammatory, acne vulgaris diagnosed as grade I or II, as the following: I) Comedones - only comedones; II) Papulopustular - comedones, papules and pustules; III) Nodulocystic - comedones, papules, pustules, nodules and cysts; IV) Conglobates - severe acne, usually affects other areas of the body, out of preference, giving comedones, papules, pustules, abscesses, confluent nodules, cysts and scars.
Agreement in compliance with the procedures of the trial and attend the clinic on certain days and times for medical evaluations and scores of injuries acne;
Signing of the Term of Free and Informed Consent and agreement of the lowest in the case of patients between 12 and 17 years.
Exclusion Criteria:
Pregnancy (pregnancy test by urinary indication to women voluntary of childbearing age);
Nursing;
Nodulocystic and Conglobates acne;
Conditions associated hormone (tireoid disease, micropolicysts ovaries, adrenal or pituitary disorders);
Drug use systemic corticosteroids, anticonvulsants, photo-sensibility and / or new drugs for up to 01 months before the selection;
Use of topical therapy, systemic or physical (cleaning of the skin) for the treatment of acne at least 01 months before the selection;
History of atopic or allergic skin;
History of hypersensitivity to Benzoyl peroxide or sulfur;
Skin Conditions active (and / or spread) that may interfere with the outcome of the study;
Beginning or end-use of contraceptives; (for females)
Sunlight intense exposure until 01 months before the assessment;
Aesthetic treatments, skin up to 01 months before the selection;
Use of specific oily cosmetic for skin / acne and makeup, facial moisturizing, etc..;
Use of the drug Acnase prior to inclusion in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sergio Schalka, MD
Phone
55-11-36546362
Email
sergio@medcinonline.com.br
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sérgio Schalka, MD
Organizational Affiliation
Medcin Instituto da Pele Ltda
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medcin Instituto da Pele Ltda.
City
Osasco
State/Province
São Paulo
ZIP/Postal Code
06023-000
Country
Brazil
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Sergio Schalka, MD
Phone
55-11-36546362
Email
sergio@medcinonline.com.br
First Name & Middle Initial & Last Name & Degree
Sergio Schalka, MD
12. IPD Sharing Statement
Learn more about this trial
Safety and Efficacy Study of Acnase Creme in the Treatment of Acne Vulgaris I and II
We'll reach out to this number within 24 hrs